Dose Insider / Analyses / Mounjaro vs Zepbound

Mounjaro vs ZepboundThe Same Drug Under Two Labels, Compared by Use, Results and Price

Updated November 20, 2026 · 17 min read · FDA labels 2026, Eli Lilly prices

Mounjaro and Zepbound are the same drug, tirzepatide, from the same company, at the same six doses. They differ in what the FDA approved them for. Mounjaro is approved to improve blood sugar control in type 2 diabetes, from age 10. Zepbound is approved for adults, to reduce weight and to treat moderate to severe obstructive sleep apnea with obesity.

1 drugtirzepatide, at the same six doses, sold as Mounjaro for type 2 diabetes and as Zepbound for weight
Weight lost in 72 weeksZepbound trials in the label, average share of starting weightNO DIABETESPlacebo−3.1%5 mg−15.0%10 mg−19.5%15 mg−20.9%WITH TYPE 2 DIABETESPlacebo−3.2%10 mg−12.8%15 mg−14.7%Weight lost in 72 weeksZepbound trials in the label, average share ofstarting weightNO DIABETESPlacebo−3.1%5 mg−15.0%10 mg−19.5%15 mg−20.9%WITH TYPE 2 DIABETESPlacebo−3.2%10 mg−12.8%15 mg−14.7%

The same drug takes off less weight when type 2 diabetes is present.

On this page

That difference decides which one insurance pays for and what it costs.

This page sets the two labels side by side: the approved uses, what each product did in its own trials, the side effects reported in each set of trials, low blood sugar, and the prices on November 20, 2026.1,2

Are Mounjaro and Zepbound the same drug?

Yes. Both labels describe tirzepatide, injected once a week, and both are made by Eli Lilly.1,2 The labels differ in approved uses and in the people the trials enrolled.

MounjaroZepbound
DrugTirzepatideTirzepatide
Approved forBlood sugar control in type 2 diabetesWeight reduction; obstructive sleep apnea with obesity
AgesAdults and children from 10Adults
Doses2.5, 5, 7.5, 10, 12.5, 15 mg2.5, 5, 7.5, 10, 12.5, 15 mg
How oftenOnce a weekOnce a week
Self-pay price from the makerNone$299 to $449 a month

Mounjaro and Zepbound prescribing information; Lilly price pages read November 20, 2026.1,2,3,4

What exactly is each approved for?

Mounjaro has one approved use: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes.1

Zepbound has two, each in combination with a reduced-calorie diet and increased physical activity. The first is to reduce excess body weight and maintain the reduction long term in adults with obesity, or with overweight and at least one weight-related condition. The second is to treat moderate to severe obstructive sleep apnea in adults with obesity.2

A person with type 2 diabetes and obesity fits both labels. One of Zepbound's two main trials enrolled exactly that group.2

The two cannot be combined. The Zepbound label says that using it together with another product containing tirzepatide, or with any GLP-1 receptor agonist, is not recommended.2

Is the dosing the same?

Yes, step for step. Both start at 2.5 mg once a week for four weeks and move to 5 mg. After at least four weeks on a dose, it can rise by 2.5 mg, up to a maximum of 15 mg.1,2 The Mounjaro label describes the 2.5 mg dose as one for starting treatment that is not intended for blood sugar control.1

One ladder, my datesBoth labels
The dose I am heading for

    Log each shot and the app keeps these dates for you.

    Open the app

    The earliest dates the labels allow, the same for both products. The prescriber decides each step.

    The difference is in why the dose goes up. On Mounjaro the label ties each increase to the need for more blood sugar control. On Zepbound the dose is chosen for weight reduction and tolerability.1,2 The pages on the Mounjaro and Zepbound schedules have each ladder in full.

    Which doses are meant for the long term?

    The Zepbound label names its maintenance doses. For weight reduction they are 5 mg, 10 mg or 15 mg once a week, chosen with treatment response and tolerability in mind. For sleep apnea they are 10 mg or 15 mg. The maximum for every use is 15 mg.2

    The Mounjaro label works differently. After 5 mg, it allows further 2.5 mg steps when additional blood sugar control is needed, up to the same 15 mg.1 A person whose blood sugar is controlled on 5 mg stays there. The page on the Zepbound maintenance dose has the trial evidence on which dose people settle at.

    What did each do in its own trials?

    The trials measured different things in different people, so the numbers answer different questions.1,2

    Trial in the labelWho5 mg10 mg15 mgPlacebo
    Mounjaro alone, 40 weeks: HbA1cType 2 diabetes−1.8 points−1.7 points−1.7 points−0.1 points
    Mounjaro alone, 40 weeks: weightType 2 diabetes−6.3 kg−7.0 kg−7.8 kg−1.0 kg
    Zepbound, 72 weeks: weightObesity or overweight, no diabetes−15.0%−19.5%−20.9%−3.1%
    Zepbound, 72 weeks: weightObesity or overweight with type 2 diabetes−12.8%−14.7%−3.2%

    Mounjaro prescribing information, Table 4, and Zepbound prescribing information, Table 2.1,2

    In the Mounjaro trial, 78% to 85% of people on the drug finished with an HbA1c below 7%, against 23% on placebo.1 Its weight results are in kilograms. From the average starting weights in the same table, they come to 7.2%, 8.1% and 9.1% of body weight for the three doses, by our arithmetic.

    The Zepbound trial was also far larger: 2,539 adults, assigned in equal numbers to 5 mg, 10 mg, 15 mg or placebo, against 121 or fewer in each arm of the Mounjaro trial.1,2

    Three things separate that from Zepbound's 15% to 21%. The Zepbound trial ran 72 weeks against 40. Its participants did not have diabetes. And they were enrolled for their weight, with a reduced-calorie diet as part of the trial.2 Zepbound's own trial in people with diabetes shows how much the population matters: 12.8% and 14.7% on the same doses that gave 19.5% and 20.9% in people without it.2

    How many people reached each weight threshold on Zepbound?

    The label's main trial enrolled 2,539 adults without diabetes and reports the share who lost at least a given percentage of their weight by week 72.2

    Lost at leastPlacebo5 mg10 mg15 mg
    5%34.5%85.1%88.9%90.9%
    10%18.8%68.5%78.1%83.5%
    15%8.8%48.0%66.6%70.6%
    20%3.1%30.0%50.1%56.7%

    Zepbound prescribing information, Table 2, Study 1.2

    The Mounjaro label has no such table for weight, because weight was not what its trials were built to test. Its counterpart is the share reaching an HbA1c below 7%: 82% on 5 mg, 85% on 10 mg and 78% on 15 mg, against 23% on placebo.1

    What do those results look like in my weight?

    Enter your weight to see the average loss in each trial as pounds or kilograms.

    Each trial in my weightLabel trials
    Unit
    Dose

    Log your weight each week and see your own line next to these averages.

    Open the app

    Three separate trials of different lengths in different people. The bars show what each trial found on average. They do not show what switching from one product to the other would do.

    Are the side effects the same?

    The list is the same, because the drug is. The reported rates are higher in the Zepbound trials, which ran about twice as long in a different population.1,2

    Same doses, two sets of trialsBoth labels
    Reaction

    Mounjaro: about 37 weeks, adults with type 2 diabetes. Zepbound: 72 weeks, adults with obesity or overweight. Each drug bar belongs with its own placebo.

    ReactionMounjaro trials: placebo, 5, 10, 15 mgZepbound trials: placebo, 5, 10, 15 mg
    Nausea4%, 12%, 15%, 18%8%, 25%, 29%, 28%
    Diarrhea9%, 12%, 13%, 17%8%, 19%, 21%, 23%
    Vomiting2%, 5%, 5%, 9%2%, 8%, 11%, 13%
    Constipation1%, 6%, 6%, 7%5%, 17%, 14%, 11%
    Hair lossNot in the table1%, 5%, 4%, 5%

    Mounjaro and Zepbound prescribing information.1,2

    Both labels say that most reports of nausea, vomiting and diarrhea came while the dose was being raised, and both carry the same boxed warning about thyroid C-cell tumors.1,2 The pages on Mounjaro side effects and the Zepbound side effects timeline go through each label.

    Side effects outside the stomach, in each label

    ReactionMounjaro trialsZepbound trials: placebo, 5, 10, 15 mg
    Reactions at the injection site3.2% against 0.4% on placebo2%, 6%, 8%, 8%
    Allergic reactions3.2% against 1.7%3%, 5%, 5%, 5%
    FatigueNot in the table3%, 5%, 6%, 7%
    DizzinessNot in the table2%, 4%, 5%, 4%
    Heart rateUp 2 to 4 beats a minute, against 1 on placebo

    Mounjaro prescribing information, section 6.1, and Zepbound prescribing information, Table 1.1,2

    Stomach and gut reactions ended treatment for 3% of people on Mounjaro 5 mg, 5.4% on 10 mg and 6.6% on 15 mg, against 0.4% on placebo.1

    Are the warnings the same?

    The warning sections of the two labels carry the same headings: thyroid C-cell tumors in a boxed warning, pancreatitis, low blood sugar with insulin or a sulfonylurea, allergic reactions, kidney injury from dehydration, severe stomach and gut reactions, diabetic retinopathy, gallbladder disease and aspiration during anesthesia or deep sedation.1,2

    Does either cause low blood sugar?

    Rarely on its own, and more often with insulin or a sulfonylurea. This is where a diabetes label and a weight label describe the same risk from two sides.1,2

    Low blood sugar in each labelBoth labels
    Situation

    At least one reading below 54 mg/dL. The trials differ in length and in the other medicines people took.

    In the Mounjaro trials nobody on the drug alone had a reading below 54 mg/dL, against 1% on placebo. Added to basal insulin the figure was 14% to 19%, against 13% on placebo with insulin.1 In the Zepbound trial in people with type 2 diabetes it was 4.2% on Zepbound and 1.3% on placebo, and 10.3% among those who also took a sulfonylurea against 2.1% among those who did not.2

    Both labels tell prescribers that the risk may be lowered by reducing the dose of the insulin or the sulfonylurea.1,2

    Are the pens and vials the same?

    Yes. The two labels describe the same four forms in the same strengths: pre-filled single-dose pens, single-dose vials, multi-dose vials and single-patient-use KwikPens. The multi-dose vial and the KwikPen each hold four doses, a month of weekly injections.1,2

    Both labels warn that a KwikPen is never shared between patients, even if the needle is changed.1,2 For people paying on their own, LillyDirect prices the Zepbound vial and KwikPen the same at each dose.3 The page on storage covers how to keep them.

    What does each cost?

    It depends on insurance, and here the two products part ways. Zepbound has a self-pay price for people paying without insurance. Mounjaro does not.3,4

    A year of eachEli Lilly, Nov 2026
    My situation
    Zepbound dose after the first months

    Log each fill and what it cost, and the app adds up your year.

    Open the app

    Thirteen four-week fills make a year. Covered figures are the floor of each savings card; a plan may leave more to pay. Zepbound self-pay prices assume each refill within 45 days.

    SituationMounjaroZepbound
    Commercial plan covers itAs little as $25; up to $150 off a month and $1,950 a yearAs little as $25; up to $100 off a month and $1,300 a year
    Commercial plan does not cover itAs low as $499 a fill; up to $647 off a month and $8,411 a yearSelf-pay: $299 for 2.5 mg, $399 for 5 mg, $449 for 7.5 to 15 mg
    No insuranceNo published priceSelf-pay, the same prices

    Lilly savings and self-pay pages, read November 20, 2026.3,4

    For someone without coverage, a year of Zepbound at self-pay prices comes to $5,087 on 5 mg and $5,637 if the dose rises to 15 mg. A year of Mounjaro at $499 a fill comes to $6,487, and only for people who have commercial insurance that does not cover it.3,4

    Zepbound's higher doses hold the $449 price only when refilled within 45 days; otherwise 7.5 mg is $499 and the three highest doses $699.3 The pages on Zepbound cost and GLP-1 cost without insurance have the detail.

    The arithmetic behind the two prices

    Zepbound's self-pay price rises with the dose and then stops: thirteen fills cost $5,087 at 5 mg and $5,837 at any dose from 7.5 mg up, once the first months are past. TrumpRx.gov lists the same starting price, $299, next to an original price of $1,087.3,5

    The Mounjaro card works by subtraction. It takes off up to $647 a month, to a floor of $499, for up to 13 fills and $8,411 in a calendar year.4 By our arithmetic the two limits together cover a pharmacy price of up to $1,146 a fill.

    Why the label decides the bill

    The Mounjaro card asks for a prescription for an approved use consistent with the label, and Mounjaro's label is for type 2 diabetes.1,4 Zepbound has its own card and its own self-pay prices.3 Which product a prescription names depends on the diagnosis it is written for, which is the prescriber's decision, and coverage is decided by the plan.

    What about sleep apnea?

    Only Zepbound is approved for it. The indication rests on two 52-week placebo-controlled trials in 469 adults with obesity and moderate to severe obstructive sleep apnea. One enrolled people who could not or would not use a PAP machine, the other people who were using one. The dose was raised over up to 20 weeks to 10 mg or 15 mg, whichever was the highest tolerated.2

    The label reports that Zepbound reduced the apnea-hypopnea index, the number of breathing interruptions per hour, more than placebo, and that more people on it reached remission or mild apnea without symptoms. In both trials people on Zepbound also had larger falls in systolic blood pressure and in a blood marker of inflammation than people on placebo. The label adds a limit: the trials did not study when or whether PAP therapy can be stopped.2

    Which label names which situation?

    Read as a table, the approved uses divide like this. It shows what each product is approved for and is not a recommendation.1,2

    SituationLabel that names it
    Type 2 diabetes, blood sugar control, adultsMounjaro
    Type 2 diabetes, age 10 to 17Mounjaro
    Obesity, or overweight with a weight-related condition, adultsZepbound
    Moderate to severe obstructive sleep apnea with obesity, adultsZepbound

    What if you have both type 2 diabetes and obesity?

    Then both labels describe you, and each has a trial in your situation. Mounjaro's trials were all in type 2 diabetes. Zepbound's second main trial enrolled adults with type 2 diabetes and obesity or overweight, and over 72 weeks they lost 12.8% of their weight on 10 mg and 14.7% on 15 mg, against 3.2% on placebo. At least 5% was lost by 79.2% and 82.8%, against 32.5%.2

    That is less than the 19.5% and 20.9% in the trial without diabetes on the same doses.2 The same pattern appears with semaglutide, as the page on Ozempic vs Wegovy shows.

    For people with diabetes both labels add the same cautions: low blood sugar when the drug is combined with insulin or a sulfonylurea, and attention to the eyes in people with a history of diabetic retinopathy.1,2

    Can you switch between Mounjaro and Zepbound?

    Neither label describes a switch, and none is needed pharmacologically: the drug and the doses are identical, so 10 mg of one is 10 mg of the other.1,2 What changes is the indication the prescription is written for, the forms on offer and the price. The dose to continue on is the prescriber's decision.

    The two are not taken together. The Zepbound label advises against using it with another product that contains tirzepatide.2

    What happens when either is stopped?

    The Zepbound label has a trial that shows it. Adults who had lost at least 5% of their weight in a 12-week diet program were assigned to Zepbound or placebo. Over the next 72 weeks the Zepbound group lost a further 18.4% and the placebo group regained 2.5%.2 The page on stopping Zepbound covers the withdrawal trial, which applies to the same drug under either name.

    Do they behave the same in the body?

    Yes. The Mounjaro label gives tirzepatide a half-life of about 5 days, which is what allows weekly dosing.1 Both labels say the drug delays the emptying of the stomach, most after the first dose and less over time, and both carry the same note for people using birth control pills: switch to a non-oral method or add a barrier method for 4 weeks after starting and after each dose increase.1,2

    The pages on how long tirzepatide stays in your system and tirzepatide and birth control apply to either name.

    How do they compare with Ozempic and Wegovy?

    Each has been tested against the matching semaglutide product. Tirzepatide at Mounjaro's doses was compared with semaglutide 1 mg, the Ozempic dose, over 40 weeks in type 2 diabetes. In that trial nausea was reported by 17% to 22% of people on tirzepatide, depending on the dose, and by 18% on semaglutide.6 The page on Ozempic vs Mounjaro has its results on blood sugar and weight. Tirzepatide for weight was compared with semaglutide 2.4 mg, the Wegovy dose, and the Wegovy vs Zepbound page covers it.

    Can either be used under 18?

    Mounjaro can, from age 10, for type 2 diabetes. In its trial of 97 patients aged 10 and older, the label reports reactions consistent with those in adults, with more vomiting, abdominal pain and low blood sugar.1 Zepbound's approved uses are for adults.2

    Short answers to common questions

    Is Zepbound just Mounjaro for weight loss?

    It is the same drug at the same doses under a different label. Zepbound is approved for weight reduction and for obstructive sleep apnea with obesity; Mounjaro is approved for type 2 diabetes.

    Which works better for weight loss, Mounjaro or Zepbound?

    They are one drug, so the question is about the trials. Zepbound's trial in people without diabetes ran 72 weeks and found 15% to 20.9% average loss. Mounjaro's 40-week diabetes trial found 6.3 to 7.8 kg, about 7% to 9%.

    Can Mounjaro be used for weight loss?

    It is not approved for it. Its one approved use is blood sugar control in type 2 diabetes.

    Can Zepbound be used for diabetes?

    It is not approved for blood sugar control. One of its trials enrolled people with type 2 diabetes and obesity or overweight, who lost 12.8% to 14.7% of their weight.

    Is the dosing different?

    No. Both start at 2.5 mg a week and can rise in 2.5 mg steps, at least four weeks apart, to 15 mg.

    Are the side effects different?

    The list is the same. Reported rates were higher in Zepbound's trials: nausea in 25% to 29%, against 12% to 18% in Mounjaro's.

    Which is cheaper without insurance?

    Zepbound, which has a self-pay price of $299 to $449 a month. Lilly publishes no self-pay price for Mounjaro.

    Which is cheaper with insurance?

    When the plan covers the product, both savings cards go as low as $25. Mounjaro's card takes off up to $150 a month and Zepbound's up to $100.

    Can you take Mounjaro and Zepbound together?

    No. The Zepbound label advises against combining it with another product that contains tirzepatide.

    If I switch from Mounjaro to Zepbound, do I start again at 2.5 mg?

    Neither label says. The drug and the doses are the same, and the dose to continue on is the prescriber's decision.

    Which one treats sleep apnea?

    Zepbound. Its label includes moderate to severe obstructive sleep apnea in adults with obesity.

    Can teenagers take them?

    Mounjaro is approved from age 10 for type 2 diabetes. Zepbound is approved for adults.

    Is Zepbound stronger than Mounjaro?

    No. The doses are identical, from 2.5 mg to 15 mg.

    Why did the Mounjaro trials show less weight loss?

    They ran 40 weeks in people with type 2 diabetes, against 72 weeks in people without it. Zepbound's own trial in people with diabetes also found less: 12.8% to 14.7%.

    Are the pens the same?

    The labels list the same forms for both: single-dose pens, single-dose vials, multi-dose vials and KwikPens.

    What is the maintenance dose of each?

    Zepbound: 5, 10 or 15 mg for weight and 10 or 15 mg for sleep apnea. Mounjaro: 5 mg, or higher in 2.5 mg steps when more blood sugar control is needed, up to 15 mg.

    Can the Mounjaro savings card be used for Zepbound?

    The two products have separate cards with separate terms. Mounjaro's requires a prescription for an approved use of Mounjaro.

    How many people lose 20% of their weight on Zepbound?

    In its main trial, 30% on 5 mg, 50.1% on 10 mg and 56.7% on 15 mg, against 3.1% on placebo.

    Does Zepbound lower blood sugar?

    Yes. Its label says Zepbound lowers blood glucose and can cause hypoglycemia. In its trial in people with type 2 diabetes, readings below 54 mg/dL were reported by 4.2% on Zepbound and 1.3% on placebo.

    How large were the trials?

    Zepbound's main trial enrolled 2,539 adults for 72 weeks. Mounjaro's main safety table pools 718 people on the drug for about 37 weeks, and its larger pool covers 5,119.

    Is the starting dose the same?

    Yes: 2.5 mg once a week for four weeks, for both.

    How long does each stay in the body?

    The same time. Tirzepatide has a half-life of about 5 days.

    Do injection site reactions differ?

    They were reported by 3.2% in the Mounjaro trials and by 6% to 8% in the longer Zepbound trials, against 0.4% and 2% on placebo.

    Can you get Mounjaro for weight loss if your plan covers it?

    Mounjaro is approved for type 2 diabetes, and its savings card asks for a prescription for an approved use. Zepbound is the tirzepatide product approved for weight.

    How the calculators work

    The calendar places the shared dose steps at 4-week intervals from the date you enter. The weight calculator multiplies your weight by each trial's average loss as a share of starting weight: 7.2%, 8.1% and 9.1% for Mounjaro 5, 10 and 15 mg, which we worked out from the label's kilograms and average starting weights, and the percentages the Zepbound label states for its two trials.

    The reaction chart sets Table 1 of each label side by side, and the low blood sugar chart shows the figures each label gives. The cost calculator adds 13 four-week fills at the prices Eli Lilly published on November 20, 2026.

    The two sets of trials differ in length, population and purpose, and the labels contain no trial comparing the two names, which are one drug. The prices carry conditions and can change.

    Sources

    1. MOUNJARO (tirzepatide) injection prescribing information, NDA 215866/S-052, revised April 2026. U.S. Food and Drug Administration; sections 1, 2, 5, 6.1, 7, 12 and 14. accessdata.fda.gov
    2. ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; sections 1, 2, 5, 6.1, 7 and 14. accessdata.fda.gov
    3. Eli Lilly and Company. LillyDirect: Zepbound self-pay prices; Zepbound coverage and savings, savings card terms. Read November 20, 2026. lilly.com
    4. Eli Lilly and Company. Mounjaro savings and resources: savings card terms. Read November 20, 2026. mounjaro.lilly.com
    5. TrumpRx.gov. Listing for Zepbound. Read November 20, 2026. trumprx.gov
    6. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med 2021;385:503-515. doi:10.1056/NEJMoa2107519

    Related analyses

    Log your doses and weight, whichever name is on the box.

    Open Dose Insider